Incidence, risk factors and clinical outcome of multidrug-resistant organisms after heart transplantation

• Published in: World journal of transplantation 2024-06, Vol.14 (2), p.93567
• Main Authors: Hatzianastasiou, Sophia, Vlachos, Paraskevas, Stravopodis, Georgios, Elaiopoulos, Dimitrios, Koukousli, Afentra, Papaparaskevas, Josef, Chamogeorgakis, Themistoklis, Papadopoulos, Kyrillos, Soulele, Theodora, Chilidou, Despoina, Kolovou, Kyriaki, Gkouziouta, Aggeliki, Bonios, Michail, Adamopoulos, Stamatios, Dimopoulos, Stavros
• Format: Article
• Language: English
• ISSN: 2220-3230; 2220-3230
• DOI: 10.5500/wjt.v14.i2.93567

Transplant recipients commonly harbor multidrug-resistant organisms (MDROs), as a result of frequent hospital admissions and increased exposure to antimicrobials and invasive procedures. To investigate the impact of patient demographic and clinical characteristics on MDRO acquisition, as well as the impact of MDRO acquisition on intensive care unit (ICU) and hospital length of stay, and on ICU mortality and 1-year mortality post heart transplantation. This retrospective cohort study analyzed 98 consecutive heart transplant patients over a ten-year period (2013-2022) in a single transplantation center. Data was collected regarding MDROs commonly encountered in critical care. Among the 98 transplanted patients (70% male), about a third (32%) acquired or already harbored MDROs upon transplantation (MDRO group), while two thirds did not (MDRO-free group). The prevalent MDROs were (14%), (12%) and (11%). Compared to MDRO-free patients, the MDRO group was characterized by higher body mass index ( = 0.002), higher rates of renal failure ( = 0.017), primary graft dysfunction (10% 4.5%, = 0.001), surgical re-exploration (34% 14%, = 0.017), mechanical circulatory support (47% 26% = 0.037) and renal replacement therapy (28% 9%, = 0.014), as well as longer extracorporeal circulation time (median 210 161 min, = 0.003). The median length of stay was longer in the MDRO group, namely ICU stay was 16 9 d in the MDRO-free group ( = 0.001), and hospital stay was 38 28 d ( = 0.006), while 1-year mortality was higher (28% 7.6%, log-rank- : 7.34). Following heart transplantation, a predominance of Gram-negative MDROs was noted. MDRO acquisition was associated with higher complication rates, prolonged ICU and total hospital stay, and higher post-transplantation mortality.